GlassScriptPhysician profile
Ruining Xu
NPI 1134957749
$1,286.85
in general payments reported to CMS, 2019-2025
15 companies · $605 in 2025
The $605 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $682 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,286.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $199.51 | 2024-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $168.90 | 2024 | Airsupra, Breztri |
| Amgen INC. | $157.13 | 2024-2025 | Tavneos, Repatha |
| Lilly USA, LLC | $156.67 | 2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Viatris Specialty LLC | $122.39 | 2025 | Yupelri |
| Novo Nordisk INC | $81.47 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $69.71 | 2025 | |
| Dexcom, INC. | $47.74 | 2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $47.39 | 2024-2025 | Heplisav-B |
| Glaxosmithkline, LLC. | $28.38 | 2025 | Trelegy Ellipta |
| Calliditas Therapeutics US INC. | $26.40 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.50 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $19.38 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $17.28 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruining Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.